Newsroom
Featured News
- Investors09 May 2025
Lotus Sets Highest-Ever April Revenue of NT$2,573 Million
- Investors09 May 2025
Lotus Pharmaceutical Achieves New First Quarter Record Results, Driven by Strong Growth in Southeast Asia and Export Markets
- Investors09 May 2025
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia
- Business08 May 2025
Lotus Enters Into Exclusive License Agreement With Supernus Pharmaceuticals for Qelbree® (viloxazine) in Major APAC Countries
- Business25 April 2025
Lotus Enters Exclusive Licensing Agreement with Henlius for Anti-PD-1 mAb Serplulimab in South Korea
- Investors10 April 2025
Lotus Announces Share Buyback Program to Enhance Shareholder Value
- Investors08 April 2025
Lotus Pharmaceutical Reaches New Height of First Quarter Revenue of NT$4.73 Billion
- Business10 March 2025
Lotus Reported Unaudited February Revenues of NT$967 Million
- Investors06 March 2025
Lotus sets new heights in 2024, achieving six consecutive years of double-digit growth
